secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001193125-25-217484
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports nex-z Phase 1 data: 92% mean TTR reduction at 24 months, 72% of patients show mNIS+7 improvement
--------------------------------------------------------------------------------

- Mean serum TTR reduction of 92% at 24 months (n=33) and 90% at 36 months (n=12) after single dose.
- 72% of evaluable patients (13/18) achieved ≥4-point improvement in mNIS+7 by month 24; most who had progressed on patisiran improved.
- 89% of all 36 patients showed improvement or stability in PND scores through 24 months; mBMI, QoL-DN, NfL all trended toward improvement.
- Nex-z generally well tolerated; infusion-related reactions mild/moderate, no discontinuations; three Grade ≥3 liver enzyme elevations resolved spontaneously.
- Phase 3 MAGNITUDE-2 enrollment (approx. 50 patients) expected to complete in H1 2026; BLA submission for ATTRv-PN targeted by 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/0001193125-25-217484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/d870108d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-217484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer